Amivas

Executive Summary

Amivas is a private pharmaceutical company established in 2017 as a US, Australian, and European joint venture, dedicated to combating severe infectious diseases with a primary focus on severe malaria. Its flagship product, Artesunate, is an approved life-saving treatment. The company leverages manufacturing partnerships and offices across North America, Europe, and Australia to distribute its medicine globally. With a lean operation and a clear mission to be a global leader in severe malaria, Amivas has carved a niche in the infectious disease space. However, its reliance on a single product and the absence of disclosed pipeline candidates pose risks. The company's profile suggests a mature stage with commercial operations, yet limited public information on financials or expansion plans.

Upcoming Catalysts (preview)

• Q4 2026Regulatory Approvals for Artesunate in New Markets70% success
• Q2 2027Supply Agreements with Global Health Organizations60% success